This company is on the watch list for 1 reason:

1) P3 results are outside the 6-9 month time-frame we like to see in our covered biotechs. CAPR will be initiating a Phase 3 by the and of Q1 2022 (hopefully). We anticipate P3 results 1H 2023. If P3 results are positive, the SP will likely spike to 5-10x current levels. This company has huge potential in the DMD space.

Once the company is closer to P3 readout, we will consider it for inclusion in our Stock Picks list.

Capricor Therapeutics (CAPR)


FN Rating


FN SummaryLead asset (CAP-1002) for DMD had very good results in a small P2 trial. Drug qualified for RMAT designation. Company must do a 65 patient P3 trial, hopefully starting in by end of Q1 2022. Good cash position, but will not last long without a partner, which management says is required before starting P3. No recent insider buying on the open market.

Table of Contents

This company hits most of the right spots!

Experienced Management

RMAT designation for their flagship drug!!

Good Phase 2

Plenty of Cash

Recent Insider Buying

Next Catalyst

Partnership Announcement - Management has not given a timeline.

Countdown Timer 👇
days until Aug 15
We chose this date as the latest date you should make an investment decision.

Interactive Chart - (chart is wrong...)

Catalyst-Chart Overlay

Caveat! Stock movement can be very finicky and, at times, seemingly random. This is FN's best explanation of the price movement.

July 15 - Capricor Announces Positive Results from its Interim Analysis in the HOPE-2 Trial

May 13 - Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in DMD Patients

Jan 12 - Capricor Collaborates with Lonza for the Development of CAP-1002.

June 21  - $75M Stock Offering

Cash on Hand


Est Monthly Cash Burn





nice cushion...

just an estimate (will increase in 2021)

Est Cash End of Dec 2021


Not enough if a P3 trial is needed and company does not find a partner.

Pipeline & Timeline

Products & Sales Potential




US Market

Global Market


For Context: Capricor Market Cap is ~ $74M as of Jan 14, 2022


Yes, we get it. This is the most dry part of the page. But, it is also the most important. Read this: Importance of Management
  • Dr. Marbán is currently serving as CEO and has served in that capacity and on the Board since November 2013.
  • As co-founder of Capricor, Inc., our wholly-owned subsidiary, Dr. Marbán has been with Capricor, Inc. since 2005 and became its Chief Executive Officer in 2010. She combines her background in research with her business experience to lead the Company and create a path to commercialization for its novel therapies.
  • Dr. Marbán was the lead negotiator in procuring the license agreements that are the foundation of the Company’s intellectual property portfolio.
  • Under her direction as CEO, the Company has been awarded approximately $30.0 million in non-dilutive grant awards which have funded our research and development programs, and a loan award that funded Capricor, Inc.’s ALLSTAR clinical trial.
  • Dr. Marbán’s deep knowledge of the cardiac space, in particular, allows her to provide unique direction for the Company’s development and growth. From 2003 to 2009, Dr. Marbán was with Excigen, Inc., a biotechnology start-up company, where she was responsible for business development, operations, pre-clinical research, and supervising the development of gene therapy products in a joint development agreement with Genzyme Corp. While at Excigen, she also negotiated a joint development and sublicense agreement with Medtronic Corp. utilizing Excigen’s technology and supervised the building of a lab in which the work was to be performed.
  • Dr. Marbán began her career in academic science, first at the Cleveland Clinic Foundation working on the biophysical properties of cardiac muscle. That work continued when she moved to a postdoctoral fellowship at Johns Hopkins University (“JHU”). While at JHU, she advanced to the rank of Research Assistant Professor in the Department of Pediatrics, continuing her work on the mechanism of contractile dysfunction in heart failure. 
  • Dr. Sudhir Borgonha serves as the VP of Clinical Development. Dr. Borgonha has held senior leadership positions in the industry across multiple geographies. Most recently, he was the Director of Translational Medicine at the Fanconi Anemia Research Fund, where he led efforts to propel a spectrum of approaches including gene therapy to treat cancer in rare diseases.
  • As the Medical Director of Strand Genomics, he oversaw the development of new technologies such as liquid biopsy and customized cancer panels, while he oversaw clinical reporting for over 5,000 patients a year (1,000 of them were rare diseases).
  • As the Medical Director of Martindale Pharma, he oversaw clinical and medical affairs of over 100 products in more than 12 countries and successfully designed, developed, and implemented multiple clinical trials at Translational Medicine Inc.
  • He was a co-founder of Angstrom Medica (Acquired by Pioneer Surgical), a biomaterials science company which he co-founded with fellow students while at MIT. Dr. Borgonha is a co-founder of ten3T, a remote cardiac monitoring company.

Company PDFs

Read all of this 👇

Corp Presentation - May 2021

Phase 2 Clinical Trial Results

Understanding the Phase 2 trial is crucial to anticipate the success of a possilbe Phase 3 trial.

Capricor is in discussions with the FDA to see if they can proceed from their Phase 2 results straight to a BLA. If they can, it will be a huge boost the the share price.

The results of the Phase 2 trial are shown below.

Due to the impressive results of CAP-1002, it qualified for RMAT! The company is currently in discussion with the FDA to determine if they can proceed with a BLA or need to conduct a Phase 3 trial.

CAPR is also doing an open label extension trial, which began in July 2020. The trial is estimated to end in Oct 2021.

Analyst Price Targets


Insider Ownership % (not precise)

Insider Transactions

No insider buys could signal that management thinks the SP will could go lower. If the SP was a bargain, management would most likely be buying stock at the market.

Institutional Holdings

Notable Institutional & Insider Holdings

Short Interest

Daily Short Volume Chart

Shares Available to Short

Sign up for Capricor emails! If you invest in this company, this is not optional.

You must stay updated on every development.

Q. What is RMAT Designation?
A. RMAT stands for “regenerative medicine advanced therapy”. This designation provides expedited programs available to sponsors of regenerative medicine therapies for serious conditions, such as DMD.  Source

Q. What does it mean for Capricor?
A. It means more frequent FDA meetings, eligibility for rolling review & priority review and accelerated approval. Most importantly, it might allow the company to skip the P3 trial and submit a BLA! If that is permitted it will save the company hundreds of millions of dollars.

Q. Does the FDA have any guidance for developing drugs for DMD?
A. Yes it does. Here is the document.

Q. Why is the FDA willing to approve select DMD drugs after only a Phase 2 trial?
A. DMD is a horrible disease. It can be summed up in this chart.

DMD Chart

If you had a child with this disease, would you want to wait 2-3 years for sponsors to finish a Phase 3 trial?  No, you would take whatever drug shows promise.

CAPR Videos

Standout Video - You need to watch this!


Phase 2 was extremely small (8 treated patients) and there is a good chance the FDA will want to see a larger trial. If this occurs it will depress the SP and the company will eventually need to dilute to complete the trial.

Email us at if you have more. We want to list all risk factors for the drug & trial.


Current DMD Drugs & Phase II Results

* Although EMFLAZA met its primary endpoint and got approval, subsequent studies have shown that the muscular strength built using this steroidal effect doesn't last over a longer duration. Another study showed no statistical difference between EMFLAZA and Placebo.
** Capricor's Phase II results would have been more compelling without 1) One non-responsive patient [who did not respond to steroids either] and, 2) A penalty assessed due to early unblinding.
*** Estimates based on early studies - no verified estimates available since these were never approved.

Disclaimer: Frugal Norwegian owns this stock

Have questions about this info? Did we miss a fact? We want to hear from you.

Like this page? Share and show others how smart you are. 🧠

Share on facebook
Share on twitter
Share on linkedin
Share on reddit
Share on email